- Home
- MOS vs ROIV Comparison
MOS vs ROIV Comparison
Compare MOS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOS | ROIV |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 14.1B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MOS | ROIV |
|---|---|---|
| Price | $24.31 | $22.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $34.50 | $24.31 |
| AVG Volume (30 Days) | 7.7M | ★ 8.2M |
| Earning Date | 11-04-2025 | 02-09-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 235.95 | N/A |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $11,894,600,000.00 | $20,329,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $2.54 | $741.42 |
| P/E Ratio | $6.29 | ★ N/A |
| Revenue Growth | ★ 3.83 | N/A |
| 52 Week Low | $22.36 | $8.73 |
| 52 Week High | $38.23 | $23.47 |
Technical Indicators
Market Signals| Indicator | MOS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 58.09 |
| Support Level | $23.69 | $21.60 |
| Resistance Level | $24.58 | $22.72 |
| Average True Range (ATR) | 0.75 | 0.82 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 32.63 | 61.77 |
Price Performance
Historical ComparisonAbout MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida and Peru and potash mines in Saskatchewan and New Mexico. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.